Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PRME files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPrime Medicine holds routine annual meeting, elects two directors through 2029
Filed June 8, 2026 · Period ending June 5, 2026 · ~1 min read
Key Changes
-
low
Michael Kelly and David Schenkein elected as Class I Directors for three-year terms ending 2029. Schenkein received notably higher withheld votes (22.6M vs 3M) but both passed comfortably.
Item 5.07 verify on EDGAR → -
low
Shareholders ratified PricewaterhouseCoopers LLP as independent auditor for 2026 with 99.7% approval (140M for, 101K against).
Item 5.07 verify on EDGAR →
Summary
Prime Medicine held its 2026 annual stockholder meeting on June 5, filing routine results two business days later. The company successfully elected two Class I directors to three-year terms and ratified its auditor with near-unanimous support. Both proposals were procedural and expected. One detail worth noting: Dr.
David Schenkein received significantly more withheld votes (22.6 million) compared to co-director Michael Kelly (3 million), though both passed easily. The disparity suggests some shareholder concern, though not enough to impact the outcome. The auditor ratification was overwhelmingly approved with less than 0.1% opposition. For retail investors, this filing has no immediate impact on operations or strategy. Watch for the company's next quarterly earnings report or pipeline updates for material business developments.
Section-by-Section Diff
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Prime Medicine held its 2026 annual meeting on June 5, 2026, electing two Class I directors and ratifying PricewaterhouseCoopers LLP as auditor.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
Proposal 1 – Each of the following nominees was elected as a Class I Director to serve until the Company’s 2029 annual meeting of stockholders, and until his respective successor shall have been duly elected and qualified, or until his earlier death, resignation or removal, based on the following votes: Class I Director Nominee | For | Withheld | Broker Non-Votes | Michael Kelly | 107,059,058 | 3,047,945 | 30,277,721 | David Schenkein, M.D. | 87,522,409 | 22,584,594 | 30,277,721
Michael Kelly and David Schenkein, M.D. were elected as Class I Directors to serve three-year terms until the 2029 annual meeting. Kelly received 107,059,058 votes for with 3,047,945 withheld, while Schenkein received 87,522,409 votes for with 22,584,594 withheld. Both directors were successfully elected despite Schenkein receiving significantly more withheld votes.
Added in current filing · verify on EDGAR →
Proposal 2 – The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified, based on the following votes: For | Against | Abstentions | 139,989,201 | 101,259 | 294,264
Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the company's independent auditor for fiscal year 2026. The proposal passed with overwhelming support, receiving 139,989,201 votes for, 101,259 votes against, and 294,264 abstentions.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify